Clinical Trials Browser

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02267915 2020-01-27

MAN2

Phase 2 Unknown

36 enrolled

Lymphoid

Recurrence, Lymphoma, Mantle-Cell

NCT03746223 2019-10-09

Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma

Phase 2 Unknown

42 enrolled

Lymphoid

Intraocular Lymphoma

NCT02060656 2019-09-19

LEGEND

Phase 2 Unknown

92 enrolled

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03777085 2019-05-30

Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)

Phase 3 Unknown

230 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

Clinical Trials

BV-AVD-R Treatment Children Hodgkin's Lymphoma

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL

CZ-WM01

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma

Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma

ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years

IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.

Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma

Relyage

Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Reduced Chemotherapy in Low Risk DLBCL

Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma

Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial

Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

Natural Killer (NK) Cell Therapy for B-Cell Malignancies

Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study

ZFCR/ZBR

ZR2-CHOP

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

LYTPET

Haploidentical Stem Cell Transplantation in Neuroblastoma

Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL

Biomarker Guided Treatment in DLBCL

R2DLBCL80

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)

DR-CHOP

NK Cells in Cord Blood Transplantation

MAN2

Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma

LEGEND

Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)